Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 1951
Effect of Initiating Metformin Vs. Sulfonylureas on the Risk of Total Knee Arthroplasty
Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes- 9:00AM-11:00AM
-
Abstract Number: 2215
Effect of Single 6 Ml Intraarticular Injection of Hylan G-F 20 in Patients with Knee Osteoarthritis: Results of a Single Centre Study
ARHP Osteoarthritis – Clinical Aspects Poster- 9:00AM-11:00AM
-
Abstract Number: 1990
Effectiveness and Durability of a Brief Multidisciplinary Treatment Program for Patients with Fibromyalgia
ARHP Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes- 9:00AM-11:00AM
-
Abstract Number: 2444
Effectiveness and Safety of CT-P13 in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Plaque Psoriasis: Observational Study in Republic of Korea
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2447
Effectiveness and Tolerability of Benepali in Rheumatoid Arthritis Patients Switched from Enbrel
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2292
Effectiveness of Common Treatment Strategies for Juvenile Arthritis in Usual Practice: Results from the Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 2280
Effectiveness of Switching to Adalimumab As the Second- and Third-Line Biological Drug in Patients with Juvenile Idiopathic Arthritis
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 2583
Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design- 9:00AM-11:00AM
-
Abstract Number: 2474
Efficacy and Safety of Extending Tocilizumab Infusion Intervals from 4 Weeks to 6 Weeks in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 1974
Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Patients: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II- 9:00AM-11:00AM
-
Abstract Number: 2445
Efficacy and Safety of Rituximab Biosimilar, CT-P10, after a Single Switch from Innovator Rituximabs in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 72 Weeks
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2167
Efficacy and Safety of Rituximab in Anti-Synthetase Positive and Negative Patients with Idiopathic Inflammatory Myopathy– a Registry-Based Study
Muscle Biology, Myositis and Myopathies Poster- 9:00AM-11:00AM
-
Abstract Number: 2482
Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2493
Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Prior Therapies